Sugi Predict

Sugi Predict / Compounds / SCHEMBL19781278

SCHEMBL19781278

SCHEMBL19781278

COc1ccc(-n2cnc3ccc(-c4ccc(C(C)C)cc4)cc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.58
▸ HTT P42858 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HPGD P15428 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ MAPK10 P53779 1/20 0.56
▸ NCOA1 Q15788 1/20 0.56
▸ NCOA3 Q9Y6Q9 1/20 0.56
▸ GSK3B P49841 5/20 0.56
▸ ATM Q13315 6/20 0.53
▸ FGFR1 P11362 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ HCAR1 Q9BXC0 1/20 0.45
▸ CDK1 P06493 1/20 0.44
▸ PRKCQ Q04759 1/20 0.44
▸ MAP3K1 Q13233 1/20 0.44
▸ TP53 P04637 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781279 0.91 KDR (0.68) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781277 0.89 HTT (0.56) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL18609552 0.86 KDR (0.74) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL18584365 0.85 KDR (0.61) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781516 0.85 GSK3B (0.61) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781594 0.82 ATM (0.58) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781592 0.82 HTT (0.67) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781511 0.82 FGFR1 (0.59) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL19781276 0.81 KDR (0.57) KDRHTTALDH1A1HPGDMAPK1
SCHEMBL21449915 0.81 ATM (0.57) KDRHTTALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193038-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-06-23 — — US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 — — US disclosed
WO-2020117794-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS, INC. (US) 2020-06-11 — — WO disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 — — US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193038-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION HAVCR2, ZC3HAV1, CD4 KDR 3639/4885HTT 4815/4885ALDH1A1 1293/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S KDR 3283/4885HTT 1337/4885ALDH1A1 1146/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S KDR 3283/4885HTT 1337/4885ALDH1A1 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.